An interventional study of Bifidobacterium longum and Placebo in Acute Pancreatitis, sponsored by The First Affiliated Hospital of Nanchang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by The First Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Pancreatitis with a site in China — 40 open to participants now, 44 under way, 2 of them phase 3. Pancreatitis · China.
Among the 104 studies in Pancreatitis with a site in China, this one is the 52nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 17 that started in 2025, is one of 48 with no phase, reaches primary completion later than 6 of the 43 other live ones, and was the 69th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →40 of the 104 studies in Pancreatitis with a site in China are open now. Recruiting first, the newest first:
Beijing Sungen Biomedical Technology Co., Ltd · Sites in China
Ages 18–75
Changhai Hospital · Sites in China
Ages 18–75
Changhai Hospital · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4–18
Jianyin Zhou · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 2 · Phase 4 11
First in 2008; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 110 across the 75 interventional studies, 350 across the 29 observational. Of the 30 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 104 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital of Nanchang University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.
The First Affiliated Hospital of Nanchang University has 7 studies filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
13 of the studies in Pancreatitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07176923CorrectSequence Therapeutics Co., LtdCS-121 APOC3 Base Editing in FCS | 2026-12 |
| NCT07093996Almazov National Medical Research CentreEndoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis | 2026-12-01 |
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT07071441Air Force Military Medical University, ChinaIndomethacin vs Diclofenac for Preventing PEP | 2026-12-31 |
| NCT07314489Shanghai Changzheng HospitalA Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 104 studies in Pancreatitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.
Participants will be randomly assigned to two groups: the intervention group and the control group. They will receive:
A total of 60 patients will be included in this study.
Rationale:The impairment of the intestinal mucosal barrier in patients with acute pancreatitis (AP) plays a crucial role in the progression to severe AP(SAP). Our previous research found that the early gut microbiota structure of AP patients is significantly different from that of healthy individuals, characterized by a marked increase in the relative abundance of conditional pathogens such as Escherichia coli and Shigella, while beneficial bacteria that produce short-chain fatty acids, such as Bifidobacterium, are significantly reduced, especially in patients with SAP. Bifidobacterium longum (BL), a well-known probiotic, has been used to treat a variety of diseases. In our previous animal experiments, we found that BL could alleviate pancreatic damage and inflammatory responses in AP mice and regulate the balance of the gut microbiota. Based on these findings, this study aims to assess the impact of BL on the clinical prognosis of AP patients through a randomized controlled trial, in order to provide a scientific basis for the application of BL in the treatment of AP and to further explore its potential clinical value.
Objective: The purpose of this clinical trial is to investigate the impact of BL on the clinical prognosis of patients with AP, to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.
Study design: Single-center, randomized, double-blind, placebo-controlled study.
Study population:60 adult patients with acute pancreatitis. Intervention: The intervention group receives standard clinical treatment plus BL capsules (10\^10 CFU), twice a day, for a total of 14 days; the control group receives standard clinical treatment plus placebo capsules, for a total of 14 days.
Main study parameters/endpoints: The primary endpoint is the number of days without SIRS within 14 days; the secondary endpoints include infectious complications (including fungal infections), parameters related to systemic inflammatory response, intestinal barrier function and gut microbiota composition, indicators related to recovery of intestinal function, antibiotic use, laboratory-related indicators, and clinical outcomes.
Safety: Throughout the study (or afterwards), treatment-emergent adverse events (TEAEs) were recorded, including gastrointestinal adverse reactions (abdominal pain, nausea, vomiting, bloating, or diarrhea) and allergic reactions, and adverse events that led to discontinuation of the study drug were documented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bifidobacterium longum capsules (10\^10 CFU) twice daily for 14 days
Dietary Supplement: Bifidobacterium longum · Combination Product: Standard clinical treatment
Placebo capsules twice daily for 14 days
Dietary Supplement: Placebo · Combination Product: Standard clinical treatment
Bifidobacterium longum
Placebo
Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
The number of days without SIRS within 14 days
Patients were randomized into the study group and remained free of SIRS up to 14 days after enrollment, with the total number of SIRS-free days counted
Time frame: From randomization to 14 days after treatment
Infectious complications
The occurence of infected pancreatic necrosis, bacteremia, pneumonia, urosepsis, and/or infected ascites,including fungal infections
Time frame: During the whole study period including follow-up of 90 days
Intestinal barrier function
Plasma D-lactate(D-lac)
Time frame: Through study completion, an average of 1 year
Intestinal barrier function
Diamine oxidase activity(DAO)
Time frame: Through study completion, an average of 1 year
Intestinal barrier function
Plasma endotoxin levels
Time frame: Through study completion, an average of 1 year
Gut microbiota composition
Fecal samples were collected from patients prior to the start of treatment, as well as on days 3, 7, and 14 after treatment. Subsequently, DNA was extracted from the feces, and the DNA was fragmented by Covaris M220 to screen for fragments of approximately 350 bp to be constructed into paired-end (Paired-End) DNA libraries. Next, libraries were constructed using NEXTFLEX Rapid DNA-Seq. Finally, these libraries were subjected to macro-genomic sequencing for in-depth analysis of microbial community structure and function in the samples.
Time frame: Baseline , 3 days,7 days and 14 days of treatment
Systemic inflammatory response parameters (SIRS)
The incidence of persistent SIRS (lasting ≥48 hours)
Time frame: Through study completion, an average of 1 year
Systemic inflammatory response parameters (SIRS)
Trends in SIRS score changes
Time frame: Through study completion, an average of 1 year
Systemic inflammatory response parameters (SIRS)
Trends in CRP level changes
Time frame: Through study completion, an average of 1 year
Gut function recovery-related indicators
Improvement in abdominal signs
Time frame: Through study completion, an average of 1 year
Antibiotic usage
The number of days of antibiotic use
Time frame: Through study completion, an average of 1 year
Mortality
Occurence of death
Time frame: During the whole study period including follow-up of 90 days
(New onset) transient/persistant (multiple) organ failure
The occurence of (new onset) transient/persistant (multiple) organ failure
Time frame: During the whole study period including follow-up of 90 days
Disease severity according to the revised Atlanta Classification
Disease severity according to the revised Atlanta Classification
Time frame: During the whole study period including follow-up of 90 days
Length of hospital and/or ICU stay
Measured in days
Time frame: Through study completion, an average of 1 year
The need (and number of) for surgical, endoscopic or radiologic interventions
The need (and number of) for surgical, endoscopic or radiologic interventions
Time frame: During the whole study period including follow-up of 90 days
Readmissions
The occurrence and number of readmissions
Time frame: During the whole study period including follow-up of 90 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Dec 2025, 9 months later.
Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 9 months is below that.
Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bifidobacterium longum
The First Affiliated Hospital of Nanchang University